Global availability of medications and health technologies for kidney care: A multinational study from the ISN-GKHA

A core feature of universal health coverage is equitable access to affordable care not exposing people to financial hardship. This study aims to provide a global overview on availability and access to medications and health technologies for delivery of optimal kidney care. An international survey of stakeholders (clinicians, policymakers, and patient advocates) from countries affiliated to the International Society of Nephrology was conducted from July to September 2022 on availability of tools and services for all aspects of kidney care and access to essential medications. Of 167 participating countries (97.4% of the global population), there were significant disparities in kidney care funding and service availability. Only 5 (n = 1) and 10% (n = 4) of countries in Latin America and Africa, respectively, publicly funded non-dialysis CKD care free at the point of delivery, compared to73% (n = 16) in Western Europe. Public funding (and free at point of delivery) for medications for dialysis and kidney transplantation was available in only 24% (n = 39) and 30% (n = 50) of countries worldwide, with the proportion increasing in line with country income levels. There was reduced capacity for the management of CKD mineral bone disease in low-income countries (LICs) - serum parathyroid hormone was available in only 26% (n = 5) of LICs and the ability to administer non-calcium-based phosphate binders and cinacalcet was also very limited in LICs [16% (n = 3) and 5% (n = 1), respectively]. Nutritional services like oral supplements were accessible in 32% (n = 6) of LICs versus 97% (n = 61) of high-income countries. This study highlights significant gaps in the global methods of funding and availability of medications, capacity for kidney disease monitoring, and capacity to treat complications of kidney disease to improve outcomes. Achieving universal and equitable access to essential medications and health technologies for kidney care is vital to tackle the rapidly growing global burden of kidney disease.

Authors

Institutions

Publication Details

Journal
PLOS Global Public Health
Published
2025-02-10
DOI
https://doi.org/10.1371/journal.pgph.0004268
Citations
2
Primary Topic
Chronic Kidney Disease and Diabetes
Type
article
Field-Weighted Citation Impact
2.86

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Global availability of medications and health technologies for kidney care: A multinational study from the ISN-GKHA

Sandrine Damster, Zibya Barday, Syed Saad, Marcello Tonelli et al.
2 citations
PLOS Global Public Health
Chronic Kidney Disease and Diabetes
2.86
article

Global availability of medications and health technologies for kidney care: A multinational study from the ISN-GKHA

Sandrine Damster, Zibya Barday, Syed Saad, Marcello Tonelli, Masaomi Nangaku, Vivekanand Jha, Dearbhla Kelly, Ikechi G. Okpechi, David Wayne Johnson, Adeera Levin, Jo‐Ann Donner, Erika Jones, Fergus Caskey, Silvia Arruebo, Feng Ye, Aminu K. Bello
article en
2 citations

Abstract

A core feature of universal health coverage is equitable access to affordable care not exposing people to financial hardship. This study aims to provide a global overview on availability and access to medications and health technologies for delivery of optimal kidney care. An international survey of stakeholders (clinicians, policymakers, and patient advocates) from countries affiliated to the International Society of Nephrology was conducted from July to September 2022 on availability of tools and services for all aspects of kidney care and access to essential medications. Of 167 participating countries (97.4% of the global population), there were significant disparities in kidney care funding and service availability. Only 5 (n = 1) and 10% (n = 4) of countries in Latin America and Africa, respectively, publicly funded non-dialysis CKD care free at the point of delivery, compared to73% (n = 16) in Western Europe. Public funding (and free at point of delivery) for medications for dialysis and kidney transplantation was available in only 24% (n = 39) and 30% (n = 50) of countries worldwide, with the proportion increasing in line with country income levels. There was reduced capacity for the management of CKD mineral bone disease in low-income countries (LICs) - serum parathyroid hormone was available in only 26% (n = 5) of LICs and the ability to administer non-calcium-based phosphate binders and cinacalcet was also very limited in LICs [16% (n = 3) and 5% (n = 1), respectively]. Nutritional services like oral supplements were accessible in 32% (n = 6) of LICs versus 97% (n = 61) of high-income countries. This study highlights significant gaps in the global methods of funding and availability of medications, capacity for kidney disease monitoring, and capacity to treat complications of kidney disease to improve outcomes. Achieving universal and equitable access to essential medications and health technologies for kidney care is vital to tackle the rapidly growing global burden of kidney disease.

PLOS Global Public HealthVol. 5(2)
Translational Research Institute (AU), University of British Columbia (CA), University of Alberta (CA), University of Cape Town (ZA), Manipal Academy of Higher Education (IN), The University of Queensland (AU), University of Calgary (CA), Princess Alexandra Hospital (AU), Groote Schuur Hospital (ZA), John Radcliffe Hospital (GB), University of Bristol (GB), University of Oxford (GB), Kidney Health Australia (AU), George Institute for Global Health (IN), Imperial College London (GB), The University of Tokyo (JP)
Amgen, Eli Lilly and Company, AstraZeneca, Heart and Stroke Foundation of Canada, International Society of Nephrology, BioCryst, Fresenius Medical Care North America, University of Alberta, Astellas Pharma, Servier, Akebia Therapeutics, Chugai Pharmaceutical, Medical Research Council, National Health and Medical Research Council, Daiichi Sankyo Europe
Openalex Percentile: Top 12%
Chronic Kidney Disease and Diabetes
2.86
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.